Clinical relevance of HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy

被引：0
|
作者：
Seo, An Na [1 ]
Yoon, Ghilsuk [1 ]
Chhun, Vireak [1 ]
Kim, Hye Jin [2 ]
Park, Jong Min [3 ]
Park, Jun Seok [2 ]
机构：
[1] Kyungpook Natl Univ, Med Ctr, Dept Pathol, Sch Med, Daegu, South Korea
[2] Kyungpook Natl Univ, Med Ctr, Colorectal Canc Ctr, Sch Med, Daegu, South Korea
[3] Cent Phys Examinat Off, Dept Radiol, Daegu, South Korea
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2017年 / 32卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-0982
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [1] HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features
    Park, Jun Seok
    Yoon, Ghilsuk
    Kim, Hye Jin
    Park, Soo Yeun
    Choi, Gyu Seog
    Kang, Min Kyu
    Kim, Jong Gwang
    Jang, Jung-Sik
    Seo, An Na
    VIRCHOWS ARCHIV, 2018, 473 (04) : 413 - 423
  • [2] HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features
    Jun Seok Park
    Ghilsuk Yoon
    Hye Jin Kim
    Soo Yeun Park
    Gyu Seog Choi
    Min Kyu Kang
    Jong Gwang Kim
    Jung-Sik Jang
    An Na Seo
    Virchows Archiv, 2018, 473 : 413 - 423
  • [3] Clinical relevance of c-MET overexpression in patients with residual rectal cancer after preoperative chemoradiotherapy
    Kang, Byung Woog
    Seo, An Na
    Hur, Keun
    Choi, Young Hun
    Lee, Eun Hye
    Kim, Jong Gwang
    Chae, Yee Soo
    Lee, Soo Jung
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Clinical Relevance of Cancer Stem Cell on Residual Disease After Preoperative Chemoradiotherapy for Rectal Cancer: A Retrospective Single Institution Study
    Yoon, GhilSuk
    Kim, Hye Jin
    Kim, Sol-Min
    Seo, An Na
    MODERN PATHOLOGY, 2015, 28 : 200A - 200A
  • [5] Clinical Relevance of Cancer Stem Cell on Residual Disease After Preoperative Chemoradiotherapy for Rectal Cancer: A Retrospective Single Institution Study
    Yoon, GhilSuk
    Kim, Hye Jin
    Kim, Sol-Min
    Seo, An Na
    LABORATORY INVESTIGATION, 2015, 95 : 200A - 200A
  • [6] Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer
    Yoon, Ghilsuk
    Kim, Sol-Min
    Kim, Hye Jin
    Seo, An Na
    TUMOR BIOLOGY, 2016, 37 (03) : 3571 - 3580
  • [7] Prediction model for ypN status after preoperative chemoradiotherapy in patients with rectal cancer
    Jwa, Eunjin
    Kim, Jong Hoon
    Han, Seungbong
    Park, Jin-hong
    Kim, Jin Cheon
    Yu, Chang Sik
    Lim, Seok-Byung
    Kim, Tae Won
    Hong, Yong Sang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [8] Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients
    Yasui, Kazuaki
    Kondou, Ryota
    Iizuka, Akira
    Miyata, Haruo
    Tanaka, Emiko
    Ashizawa, Tadashi
    Nagashima, Takeshi
    Ohshima, Keiichi
    Urakami, Kenichi
    Kusuhara, Masatoshi
    Muramatsu, Koji
    Sugino, Takashi
    Yamguchi, Ken
    Mori, Keita
    Harada, Hideyuki
    Nishimura, Tetsuo
    Kagawa, Hiroyasu
    Yamakawa, Yushi
    Hino, Hitoshi
    Shiomi, Akio
    Akiyama, Yasuto
    JOURNAL OF RADIATION RESEARCH, 2020, 61 (05) : 766 - 775
  • [9] Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy
    Banna, Giuseppe L.
    Gulio, Giuseppe
    Masci, Giovanna
    Simonelli, Matteo
    Rimassa, Lorenza
    Di Tommaso, Luca
    Bettio, Daniela
    Roncalli, Massimo
    Santoro, Armando
    ANNALS OF ONCOLOGY, 2006, 17 : 105 - 105
  • [10] Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status
    Yoon, Ghilsuk
    Lee, Hwayoung
    Kim, Jae-Hoon
    Hur, Keun
    Seo, An Na
    TUMOR BIOLOGY, 2016, 37 (08) : 10209 - 10218
12345